Objectives: Mycobacterium abscessus is innately resistant to a variety of drugs thereby limiting therapeutic options. Bacterial resistance to aminoglycosides (AGs) is conferred mainly by AG-modifying enzymes, which often have overlapping activities. Several putative AG-modifying enzymes are encoded in the genome of M. abscessus. The aim of this study was to investigate the molecular basis underlying AG resistance in M. abscessus.
Introduction
Mycobacterium abscessus is a rapid growing mycobacterium of increasing medical importance. This emerging pathogen causes bronchopulmonary infections in individuals with cystic fibrosis 1 and chronic pulmonary disease, such as pneumoconiosis and bronchiectasis. 2 It also causes severe infections following surgery, transplantation, tattooing and mesotherapy. [3] [4] [5] [6] [7] [8] Treatment of an M. abscessus infection is difficult due to the bacteria's high degree of intrinsic resistance to chemotherapeutic agents. 9 The pathogen is naturally resistant to many major classes of antibiotics used for the treatment of Gram-positive and Gram-negative bacterial infections, such as b-lactams, aminoglycosides (AGs) (kanamycin B, gentamicin C) and macrolides (erythromycin). In addition, it is also resistant to first-line TB drugs, for instance isoniazid and rifampicin. M. abscessus has been called an antibiotic nightmare since treatment options against M. abscessus infection are more limited than for Mycobacterium tuberculosis infection. 10 While no standard treatment recommendations for pulmonary M. abscessus infections have yet been established, current guidelines propose administration of an oral macrolide (clarithromycin or azithromycin) for clinical isolates susceptible to macrolides and the intravenous AG amikacin in combination with a parenteral b-lactam antibiotic, cefoxitin or imipenem. 11 AGs and macrolides inhibit protein biosynthesis by binding to the small and large ribosomal subunit, respectively. Clinically acquired pan-AG and pan-macrolide resistance has been attributed to mutations in ribosomal RNA genes rrs and rrl, coding for 16S and 23S rRNA, respectively. Owing to the presence of a single ribosomal RNA (rrn) operon, corresponding resistance mutations have readily been observed in M. abscessus. [12] [13] [14] However, distinct mechanisms have been proposed to be responsible for innate AG resistance in M. abscessus. 9, 15 AG antibiotics form a group of hydrophilic molecules, consisting of a characteristic, central aminocyclitol linked to one or more amino sugars by pseudoglycosidic bond(s). They inhibit prokaryotic protein biosynthesis by binding to the A-site of the 16S rRNA. AGs are active against a wide range of aerobic Gramnegative bacilli, staphylococci and mycobacteria. Resistance to AGs is due to low uptake, increased efflux, target modification or enzyme-mediated drug modification. Originally isolated from microorganisms (mainly Streptomyces spp.), semi-synthetic derivatives of AGs have been generated to improve the pharmacological properties of the drugs and to overcome bacterial resistance mechanisms. 16 The semi-synthetic drug amikacin is a cornerstone of M. abscessus infection therapy, whereas other AGs are not frequently used. M. abscessus genome annotation suggests the presence of various AG-modifying enzymes such as AG phosphotransferases, AG nucleotidyltransferases and AG acetyltransferases (AACs). 17 The individual contribution of these genes to M. abscessus AG susceptibility cannot be predicted reliably due to overlapping specificities.
Elucidation of gene functions, drug target and host-pathogen interaction heavily relies on the generation of isogenic mutants. Usually, antibiotic resistance markers are used for the primary selection of transformants. Tools for genetic manipulation of mycobacteria in general, and M. tuberculosis in particular, have been developed during the past two or three decades. 18 In contrast, genetic manipulation of M. abscessus has been reported to be very difficult and attempts have often been unsuccessful, [19] [20] [21] although some progress has been made. [22] [23] [24] [25] We recently developed genetic tools for M. abscessus 26 and have now exploited them for elucidating intrinsic AG resistance mechanisms in the M. abscessus ATCC 19977 type strain. We particularly addressed the role of putative AACs in M. abscessus AG and capreomycin resistance. We generated single, double and triple mutants of M. abscessus by targeted deletion of three genes potentially involved in AG resistance and characterized those mutants by phenotypic drug susceptibility testing. Interestingly, a double mutant proved to be susceptible to a wide variety of AGs and to the peptide antibiotic capreomycin.
Materials and methods

Bacterial strains and media
The Escherichia coli laboratory strain XL1-Blue MRF 0 (Stratagene, Switzerland) and ER2925 dam # , dcm # were used for cloning and propagation of plasmids. The strains were grown in LB medium containing one of the antibiotics: ampicillin (120 mg/L), kanamycin A (50 mg/L), apramycin (50 mg/L) or hygromycin B (100 mg/L). Antibiotics (Sigma-Aldrich, Switzerland) were dissolved in water according to the manufacturer's recommendations and stored as a stock solution until usage.
M. abscessus ATCC 19977 was grown in Middlebrook 7H9-OADC-Tween 80 or LB containing one of the antibiotics, if required: kanamycin A (50 mg/L), apramycin (50 mg/L) or isoniazid (32 mg/L). For preparation of electrocompetent cells two cell culture flasks each containing 200 mL of 7H9-OADC-Tween 80 were inoculated 1:100, incubated at 37 C and gently shaken daily. When OD 600 reached 0.4-0.8, cultures were set on ice for 90 min. Bacteria were harvested by centrifugation and repeatedly resuspended in ice-cold glycerol (10% v/v) while gradually reducing the volume. 27 Finally, bacteria were resuspended in 2 mL of glycerol (10% v/v) and either frozen in liquid nitrogen or directly used for electroporation, as we recently described. 26 Genomic DNA was isolated by phenol/chloroform/isoamyl alcohol extraction, as described previously. 28 
Generation of vectors
The apramycin resistance cassette from plasmid pSET152 29 was PCR amplified (primers Apr_F and Apr_R) (see Table S1 , available as Supplementary data at JAC Online, for list of primers) and cloned as a 1 kbp SpeI fragment into SpeI-digested plasmid pMV361 30 to result in plasmid pMV361-apr.
An M. tuberculosis katG fragment (2.8 kbp) was PCR amplified (primers KatG_F and KatG_R) and cloned into pGEM-T-easy to result in pGEM-T-katG. Subsequently, the 2.8 kbp SwaI-katG-HpaI fragment was cloned into HpaIlinearized pMV361-apr to result in pMV361-apr-katG. Removal of mycobacteriophage attP/int from plasmid pMV361-apr-katG by XbaI excision and self-ligation of the vector backbone resulted in the prototype suicide vector pSE-apr-katG into which flanking regions of the target genes were cloned. 0 flanking sequence of MAB_4124 (eis1) were PCR amplified (primers 4124_UP_F, 4124_UP_R and 4124_DW_F, 4124_DW_R) using genomic DNA from M. abscessus ATCC 19977. Fragments were stepwise cloned with corresponding enzymes into saving vectors and subsequently into NotI/XbaIdigested vector pSE-apr-katG to result in knockout vector pSE-Deis1. The eis1 allele was deleted from the M. abscessus ATCC 19977 chromosome using apramycin (positive) and isoniazid (negative) selection. Deletion was confirmed by Southern blot analysis using Van91I-digested genomic DNA and a 0.3 kbp 5 0 eis1 fragment amplified with primers P_4124_F and P_4124_R.
Disruption of MAB_4532c (eis2) in M. abscessus 0 flanking sequence of MAB_4532c (eis2) were PCR amplified (primers 4532c_UP_F, 4532c_UP_R and 4532c_DW_F, 4532c_DW_R) using genomic DNA from M. abscessus ATCC 19977. Fragments were stepwise cloned into vector pSE-apr-katG resulting in knockout vector pSE-Deis2. The eis2 allele was deleted from the M. abscessus ATCC 19977 chromosome using apramycin (positive) and isoniazid (negative) selection. Deletion was confirmed by Southern blot analysis with Van91I-digested genomic DNA and a 0.3 kbp 5 0 eis2 probe amplified with primers P_4532c_F and P_4532c_R. For complementation a 1.3 kbp fragment from M. abscessus ATCC 19977 (position 4614320-4615651) spanning the entire eis2 gene was PCR amplified (primers C_4532c_F, C_4532c_R) and cloned via HindIII into pJB-apr vector to result in pJB-apr-eis2 complementation vector. M. abscessus Deis2 was Rominski et al.
transformed with pJB-apr-eis2 and control vector pJB-apr, respectively. Genetic complementation was confirmed by Southern blot analysis.
MIC assays
Kanamycin B, tobramycin, dibekacin, arbekacin, gentamicin C [C1 (,45%), C2 (,35%) and C1a (,30%)], isepamicin, amikacin, kanamycin A, apramycin, streptomycin, hygromycin B and capreomycin were bought from Sigma-Aldrich. Antibiotics were dissolved in water according to the manufacturer's recommendations, were filter sterilized, aliquoted into stock solutions and stored at -20 C. MIC determination for M. abscessus strains was done according to CLSI guidelines 31 and basically as we previously described. 26 
Results
Targeted inactivation of putative AG resistance genes of M. abscessus
Genome annotation, 17 genome analysis and AG drug susceptibility testing 15 suggest the presence of several putative AACs in M. abscessus. ORF MAB_4395 is annotated as a putative AG 2 17 while MAB_4124 and MAB_4532c show homology to eis. Eis (enhanced intracellular survival) proteins are found in a variety of mycobacterial and non-mycobacterial species. 32, 33 Overexpression of Eis (Rv2416c) confers increased kanamycin resistance on M. tuberculosis.
34 M. abscessus MAB_4124 is the closest homologue of M. tuberculosis Rv2416c (33% identity), which we therefore name eis1. Interestingly, a second Eis homologue encoded by MAB_4532c is present in the M. abscessus genome. In a phylogenetic tree constructed from 29 Eis homologues, 33 MAB_4532c (which we name Eis2) is clustered with Eis homologues from the non-mycobacterial clade instead of the mycobacterial group, e.g. M. abscessus Eis2 shows 23% identity to Anabaena variabilis Eis. We addressed the role of the three acetyltransferases in M. abscessus AG resistance by engineering and characterizing corresponding unmarked deletion mutants in the M. abscessus ATCC 19977 type strain.
Flanking fragments of the target genes aac(2 0 ), eis1 and eis2 were cloned into plasmid pSE-apr-katG to result in suicide vectors pSE-Daac, pSE-Deis1 and pSE-Deis2, respectively. These flanking fragments enable homologous recombination of the suicide vector. The apramycin resistance cassette of the vector backbone facilitates selection of single crossover transformants resulting from vector integration by intermolecular homologous recombination at the target locus. Catalase-peroxidase KatG, the activator of the TB prodrug isoniazid, 35 serves as a negative selectable marker since it sensitizes M. abscessus to isoniazid. Expression of KatG facilitates screening for deletion mutants resulting from resolving the integration of the suicide vector by a second intramolecular homologous recombination. 26 Electrocompetent M. abscessus were transformed and apramycin selection and Southern blot analysis were applied to identify single crossover transformants. Subsequently, isoniazid counterselection and Southern blot analysis were applied for the identification of M. abscessus Daac(2 0 ), M. abscessus Deis1 and M. abscessus Deis2 mutants (Figure 1) . Deletion mutants showing a phenotype [M. abscessus Daac(2 0 ) and M. abscessus Deis2] were transformed with single copy, i.e. pMV361-based complementation and control vectors, respectively (see Table 1 for list of strains and Table 2 (Figure 2 ).
Drug susceptibility testing of M. abscessus mutant strains
Drug susceptibility of M. abscessus strains towards a variety of structurally similar 4,6-disubstituted AGs (Figure 3 ) was tested in CAMHB. In addition, drug susceptibility to structurally atypical AGs apramycin, hygromycin B and streptomycin and to the peptide antibiotic capreomycin (also inhibiting protein biosynthesis by interaction with the 16S rRNA A-site) was determined. Growth was judged after 3, 5, 7 and 12 days of incubation and the MICs were determined. The median MIC values on day 5 are shown in Table 3 .
The MIC values read at all timepoints are shown in Table S2 . A variety of mutant phenotypes was observed. Deletion of aac(2 0 ) increased susceptibility of M. abscessus to kanamycin B (64-fold), tobramycin (32-fold), dibekacin (16-fold) and gentamicin C (4-fold). Deletion of aac(2 0 ) did not affect MICs of arbekacin, isepamicin, amikacin, kanamycin A, apramycin, streptomycin, hygromycin B and capreomycin (Table 3 ). The tobramycin, dibekacin and gentamicin C WT phenotype was restored upon transformation with the complementation vector pMV361-aac(2 0 ), but not by transformation with the backbone control vector pMV361 (Table S2 ). The presence of a kanamycin resistance cassette [aph (3 0 )] in the backbone of the complementation vector interfered with susceptibility testing for kanamycin A and B and MICs of these compounds are therefore not reported. Deletion of eis1 did not result in a detectable phenotype; MICs of none of the tested antibiotics were altered. Owing to the absence of a phenotype, no complementation vector was constructed. Deletion of eis2 increased susceptibility of M. abscessus to several AGs. However, the susceptibility pattern of M. abscessus Deis2 clearly differed from that of M. abscessus Daac(2 0 ). Deletion of eis2 increased susceptibility to kanamycin B (4-fold), amikacin (8-fold), hygromycin B (16-fold) and capreomycin (32-fold). Deletion of eis2 did not affect susceptibility to tobramycin, dibekacin, arbekacin, gentamicin C, isepamicin, kanamycin A, apramycin and streptomycin. Transformation of the Deis2 mutant with the complementation vector pJB-apr-eis2, but not with the vector backbone pJB-apr, restored WT MICs of amikacin, hygromycin B and capreomycin (Table S2 ). The presence of the apramycin resistance cassette in the backbone of the complementation vector interfered with susceptibility testing for kanamycin (A and B), tobramycin, dibekacin, gentamicin C and apramycin, and therefore MIC values of these antibiotics are not reported. 
Discussion
M. abscessus is a pathogen of increasing medical importance, particularly in individuals with chronic pulmonary disease. The high level of intrinsic resistance to many classes of antibiotics restricts antibiotic therapy. 9 Genome annotation, 17 susceptibility testing and biochemical assays predicted a role for 2 0 -N-acetyltransferase in M. abscessus AG resistance. 15 A candidate gene eventually responsible for the increased MIC levels of 2 0 -amino-AGs, MAB_4395 [aac(2 0 )] was inactivated by targeted gene deletion. Comparison of WT and mutant strains by phenotypic susceptibility testing demonstrated a decreased MIC for the mutant of a variety of drugs characterized by a 2 0 -amino group (kanamycin B, tobramycin, dibekacin, gentamicin C). Kanamycin A, which differs from kanamycin B by a single structural feature (2 0 -OH group instead of a 2 0 -amino group), has a lower MIC for the WT strain than kanamycin B and its MIC is not further decreased by aac(2 0 ) deletion. These data corroborate the hypothesis that MAB_4395 encodes a functional AG 2 0 -N-acetyltransferase, which renders M. abscessus fragment from the 5 0 aac(2 0 ) flanking region. Based on M. abscessus genome annotation and vector sequence, the pattern is consistent with hybridization to a 2.5 kbp fragment of the WT parental strain, to the 2.1 and 2.5 kbp fragments after site-specific homologous recombination (single crossover; sco), to a 2. 
Deis1 Deis2
M. abscessus aac(2 0 ) eis1 eis2 triple deletion mutant; derivative of M. abscessus Deis1 Deis2 this study
M. abscessus aac(2 0 ) mutant transformed with complementation vector pMV361-aac(2 0 ) this study M. abscessus Daac(2 0 ) pMV361 M. abscessus aac(2 0 ) mutant transformed with pMV361 control vector this study M. abscessus Deis2 pJB-apr-eis2 M. abscessus Deis2 mutant transformed with complementation vector pJB-apr-eis2 this study M. abscessus Deis2 pJB-apr M. abscessus Deis2 mutant transformed with control vector pJB-apr this study Rominski et al. 
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The M. abscessus Deis1 mutant did not show any resistance phenotype and therefore does not contribute to AG resistance, at least not during in vitro growth. Expression studies and biochemical assays would be required to address the physiological and enzymatic function of Eis1. It may be hypothesized that promoter-up mutations might increase AG resistance. This hypothesis could also be addressed by transformation of WT strains with multi-copy vectors containing eis1. However besides AAC(2 0 )-mediated AG resistance, M. abscessus possesses at least a second mechanism of AG resistance, which is mediated by Eis2. The Deis2 mutant showed increased susceptibility to the peptide antibiotic capreomycin and to a distinct and more heterogeneous group of AGs: kanamycin B, amikacin and hygromycin B. Eis proteins of different origin have been shown to have multiple AG-and capreomycin-acetylating activities, e.g. M. tuberculosis and M. smegmatis Eis tri-acetylate neamine in a sequential manner, first at position 2 0 , then at position 6 0 and finally at position 1. The number of acetylations depends on the AG itself, but also on the biological origin of the enzyme. Up to four acetyl residues may be transferred to tobramycin by M. tuberculosis Eis and M. smegmatis Eis, respectively. 33, 37, 38 Hygromycin is mono-and di-acetylated by M. smegmatis and M. tuberculosis Eis, respectively. Apramycin is diacetylated by M. smegmatis, but is not a substrate for M. tuberculosis Eis. M. abscessus Eis2 does not inactivate apramycin (identical MICs for the WT strain and the Deis2 mutant), although this does not exclude that apramycin is an M. abscessus Eis2 substrate. Corresponding acetylations might just not affect antibacterial activity. A combined application of an AAC(2 0 ) inhibitor together with specific NH 2 -AGs (e.g. kanamycin B and gentamicin C) could enhance the activity of these AGs. Administration of an Eis2 inhibitor could enhance the activity of capreomycin and amikacin, the latter being a cornerstone for treatment of M. abscessus infections. 39 As opposed to several 2-deoxystreptamine AGs, streptomycin MICs for the mutant strains remained at the high WT MIC level, pointing to a distinct streptomycin resistance mechanism in M. abscessus. Our study demonstrates that apramycin, an AG with little ototoxicity, 40 arbekacin, isepamicin and kanamycin A exhibit excellent in vitro activities against the M. abscessus ATCC 19977 type strain and that the activity of these drugs is not affected by AAC(2 0 ) and Eis proteins, respectively. Our data further support MIC determination of these AGs for a broader set of M. abscessus clinical isolates. 15 The results from the suggested in vitro studies may provide a rational basis for designing clinical trials aiming at implementation of improved treatment regimens against one of the most drug-resistant pathogens, M. abscessus. For a complete overview of MIC results from three independent experiments judged at days 3, 5, 7 and 12 see Table S2 . For phenotype of single deletion mutants transformed with complementation vectors and control vectors also see Table S2 .
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